| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
| US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
| US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
|
US8895756 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
|
US8791270 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
|
US8609863 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
| US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(4 years from now) | |
| US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(4 years from now) | |
| US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(4 years from now) | |
| US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(5 years from now) | |
|
US8445524 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
|
US8669279 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
|
US8883836 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
|
US9533955 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
|
US8344006 (Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(5 years from now) | |
| US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(6 years from now) | |
|
US8436190 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(7 years from now) | |
Treanda is owned by Cephalon.
Treanda contains Bendamustine Hydrochloride.
Treanda has a total of 18 drug patents out of which 0 drug patents have expired.
Treanda was authorised for market use on 01 May, 2009.
Treanda is available in powder;iv (infusion), solution;iv (infusion) dosage forms.
Treanda can be used as for use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl), for use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma, for use in the treatment of patients with chronic lymphocytic leukemia (cll).
Drug patent challenges can be filed against Treanda from 02 May, 2015.
The generics of Treanda are possible to be released after 26 April, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-580) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | Mar 20, 2015 |
| Pediatric Exclusivity(PED) | Sep 20, 2013 |
| ODE*(ODE*) | Dec 07, 2022 |
| New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell...
Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)
TREANDA family patents
